

Election of Faculty Members and Fellows

The following awards were approved by the Faculty Boards of 25 July and 26 September 2000:

Honorary Fellowship

Professor Alasdair M. Breckenridge

Honorary Membership

Professor Kenneth D. MacRae

Dr Sam Salek

Membership by Distinction

Professor Richard D. Farmer

Dr Archibald Peter Fletcher

Dr Jane N. Zuckerman

Ordinary Fellowship

Dr Charles M. Beasley

Dr Carlo A. Berti

Dr Thomas D. Bethke

Dr Jacques Bons

Dr John R. Bratty

Dr Helen A. Coloquhoun

Dr José Luis De Almeida

Dr Pierre F. Dodion

Dr Juergen K. Froehlich

Dr Neil D. Garbett

Dr Christina Ghezzi

Professor Michael H. Habs

Dr Stephen F. Hobbiger

Dr John Hutchison

Dr Alan T. Irvine

Dr Bodo A. Jager

Professor Kewal K. Jain

Dr Alan J. Lenox-Smith

Dr Fabian Llorens

Dr Graham S. May

Dr Peter J. Moore

Dr Christopher G. Muldoon

Dr Gunnar Olsson

Dr Richard W. Peck

Dr Alison J. Pilgrim

Dr Paul R. Pilot

Dr Frank E. Rathgeb

Dr Stefano M. Rossetti

Dr Michael T. Sweeney

Dr Francis C. Upchurch

Dr Stephen D. Wise

Dr Stephen Wright

Forthcoming meeting

The United Kingdom Drug Utilisation Research Group will be holding its 12th Annual Scientific Meeting and AGM 'Prescribing in the consumer age' on 15 December 2000 at the Royal Society of Medicine in London.

Speakers: Mr Michael Bailey, Past President, ABPI; Professor Mike Drummond, University of York; Mr Peter Cardy, The Multiple Sclerosis Society; Mr Christopher Newdick, University of Reading; Mr Andy McKeon, Department

of Health. Further information is available from Dr John Ferguson, john.ferguson@ppa.nhs.uk or lynne.davies@ppa.nhs.uk; website: www.ukdurg.org.

Ethical considerations in HIV preventive vaccine research

The Joint United Nations Programme on HIV/AIDS (UNAIDS) published a guidance document in May 2000 that highlights some of the critical ethical principles that ought to be considered when developing a HIV vaccine. It contains 18 guidance points that attempt to encompass all ethical facets of vaccine development, inevitably producing rather arid, verbose and politically correct statements.

However, the text itself offers some important and well-reasoned principles, such as:

‘Though HIV vaccines should benefit all those in need, it is imperative that they benefit the populations at greatest risk of infection. Thus, HIV vaccine development should ensure that the vaccines are appropriate for use among such populations, among which it will be necessary to

conduct trials; and, when developed, they should be made available and affordable to such populations.’

Therefore, the 48-page booklet is a valuable contribution to a debate on issues that will soon be a reality.